Ocuphire Pharma(OCUP) - 2023 Q4 - Annual Report

FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the Fiscal Year Ended December 31, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from _____ to _____ Commission File No. 001-34079 Ocuphire Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3516358 (State or other jurisdiction of i ...